Cabotegravir HIV PrEP Effective Among U.S. Women Despite Treatment Interruptions
(MedPage Today) -- No women taking long-acting cabotegravir (Apretude) for HIV pre-exposure prophylaxis (PrEP) developed an HIV infection despite short delays before some maintenance injections, according to a U.S. study of routine clinical care...
A U.S. study of routine clinical care involving 315 women who started long-acting cabotegravir injections for HIV pre-exposure prophylaxis (PrEP) in 2021-2024 found no cases of incident HIV despite short delays before some maintenance injections. The study, presented at the International AIDS Conference, showed that despite treatment interruptions, none of the women on cabotegravir PrEP acquired HIV during the study period, demonstrating the high real-world effectiveness of this method.
Long-acting injectable cabotegravir is administered as a monthly injection for the first two months, then every two months afterwards. While 88% of the 1,193 maintenance injections were on time, 44% of women had at least one delayed injection, which had a median delay of 8 days. This study highlights that PrEP works for cisgender and transgender women in the U.S., even with treatment interruptions, and that patients continue to find cabotegravir an effective PrEP option.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
